🇺🇸 Morphine Sulfate Sustained-Release Tablet in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 3 reports (23.08%)
  2. Hypokalaemia — 2 reports (15.38%)
  3. Acute Kidney Injury — 1 report (7.69%)
  4. Agranulocytosis — 1 report (7.69%)
  5. Alanine Aminotransferase Increased — 1 report (7.69%)
  6. Bacterial Sepsis — 1 report (7.69%)
  7. Blood Alkaline Phosphatase Increased — 1 report (7.69%)
  8. Blood Bilirubin Increased — 1 report (7.69%)
  9. Blood Creatinine Increased — 1 report (7.69%)
  10. Diarrhoea — 1 report (7.69%)

Source database →

Other Pain Management approved in United States

Frequently asked questions

Is Morphine Sulfate Sustained-Release Tablet approved in United States?

Morphine Sulfate Sustained-Release Tablet does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Morphine Sulfate Sustained-Release Tablet in United States?

Mundipharma (China) Pharmaceutical Co. Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.